We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vyndamax

News List

Pfizer's 4Q Revenues up 12% contractpharma
February 10, 2021
COVID-19 vaccine BNT162b2, which was granted an EUA in the U.S. in December 2020, contributed $154 million in sales in the quarter.
Financial Report; Pfizer contractpharma
November 06, 2020
Revenues down 4% in the quarter to $12.1 billion.
FDA OKs Vyndaqel and Vyndamax as First Treatments for Rare Heart Disease drugs
June 03, 2019
FDA OKs Vyndaqel and Vyndamax as First Treatments for Rare Heart Disease.
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease pharmatimes
May 09, 2019
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease.
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis drugs
May 08, 2019
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis drugs
May 07, 2019
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis.